Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Tom Robinson, vice president of global access at JDRF, discusess plans to update the Type 1 Diabetes (T1D) Index each year.
Transcript
Will the T1D Index be updated annually?
That's the plan, we plan to refresh it once a year. I think for the first few years, at least, we'll be doing 2 things: We'll be refreshing the latest data and latest literature, but we'll also be taking into account feedback that we received and also some of our own ambitions to improve on what we started with.
We want to make it more granular and specific and accurate, like state-level data or take into account genetic backgrounds and so forth. We want to quantify more of the burden of type 1, so the economic burdens, quality of life burdens, psychosocial burdens. I want to have 1 number that's all the ways in which type 1 steals from us in 1 number, that would be a really powerful place to get to. Currently, we have all the physical elements, but I want to have the full suite.
The last thing is we're looking at ways to turn the index into a way that we can track progress. So, using a combination of surveys and direct interviews and industry reports, industry data to say, how is the prevailing standard of care changing in different countries and, therefore, how do we expect that's affecting mortality rates and complication rates and the experience living with type 1, so that we can actually look and say, "Oh, wow, over the last 5 years there's been this incredible progress in India, but we've gone backwards in this state in America." Being able to really hold our own feet to the fire and also the global community's feet to the fire in making progress.
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More